| Ataxin-7 | |
|---|---|
| Gene | ATXN7 |
| UniProt | O75376 |
| PDB | N/A |
| Mol. Weight | 130 kDa (normal), variable with expansion |
| Localization | Nucleus (nuclear matrix, nucleolus) |
| Family | Ataxin-7 family |
| Diseases | Spinocerebellar Ataxia Type 7 (SCA7) |
| Aliases | ATXN7, SCA7, Olivopontocerebellar atrophy 3 |
Ataxin-7 is a protein encoded by the ATXN7 gene, located on chromosome 3p12. It belongs to the ataxin family of proteins, which are characterized by a polymorphic glutamine (Q) tract in their N-terminal region. Ataxin-7 is a critical component of the transcriptional co-activator complex known as SAGA (Spt-Ada-Gcn5 acetyltransferase) and plays essential roles in gene expression regulation, chromatin remodeling, and neuronal survival. Expansion of a CAG trinucleotide repeat in the ATXN7 gene leads to Spinocerebellar Ataxia Type 7 (SCA7), a fatal autosomal dominant neurodegenerative disorder characterized by progressive cerebellar ataxia, retinal degeneration, and eventual complete paralysis.[1]
Ataxin-7 is a protein of approximately 130 kDa (in its normal, non-expanded form) encoded by the ATXN7 gene on chromosome 3p12. This protein is primarily localized to the nucleus, particularly the nuclear matrix and nucleolus, where it functions as a structural and functional component of the SAGA transcriptional co-activator complex.[2]
In its normal form, ataxin-7 contains a polyglutamine (polyQ) tract of 4-35 glutamine residues. Disease-causing expansions result in an expanded polyQ tract (>36 Q residues), leading to toxic gain-of-function, protein misfolding, aggregation, and neuronal dysfunction. The length of the polyQ expansion correlates inversely with age of onset—longer expansions result in earlier disease onset, sometimes in childhood or infancy (infantile SCA7), while shorter expansions may present in adulthood.[3]
SCA7 is unique among polyglutamine diseases for its combination of cerebellar degeneration and progressive retinal photoreceptor loss, making it one of the most devastating inherited neurodegenerative disorders.[4]
The ATXN7 gene spans approximately 44 kb and consists of 13 exons. The first exon contains the CAG repeat region encoding the polyglutamine tract. The gene is expressed ubiquitously but shows highest expression in the cerebellum (Purkinje cells), retina (photoreceptors), cerebral cortex, and motor neurons.[5]
| Tissue | Expression Level |
|---|---|
| Cerebellum (Purkinje cells) | High |
| Retina (photoreceptors) | High |
| Cerebral cortex | Moderate |
| Heart | Low |
| Liver | Low |
| Skeletal muscle | Low |
Ataxin-7 is a 892-amino acid protein with several distinct domains:
N-terminal Polyglutamine (polyQ) Tract (residues 1-50)
Ataxin-7 Domain (residues 200-350)
SAGA-Sgf29 Domain (residues 400-500)
C-terminal Region (residues 600-892)
The protein localizes primarily to the nuclear matrix and nucleolus, where it associates with the SAGA complex. The SAGA complex is a multifunctional transcriptional co-activator that possesses histone acetyltransferase (HAT) and deubiquitinase (DUB) activities, both of which are critical for transcriptional regulation.[6]
Ataxin-7 is a core structural component of the SAGA (Spt-Ada-Gcn5 acetyltransferase) co-activator complex, which regulates gene expression through chromatin remodeling:
Histone Acetylation: The SAGA complex acetylates histones (particularly H3 and H2B) through its GCN5 catalytic subunit, promoting an open chromatin state and facilitating transcription initiation.
Histone Deubiquitination: SAGA also removes ubiquitin from histone H2B (H2Bub1) and H2A, regulating transcription elongation and DNA damage response.
Transcriptional Co-activation: Ataxin-7 bridges interactions between transcription factors and the SAGA chromatin-modifying machinery, enabling precise gene expression programs essential for neuronal survival.[7]
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| SAGA Complex (GCN5, ADA2, SGF29) | Structural component | Transcriptional co-activation |
| p53 | Direct binding | Pro-apoptotic gene regulation |
| CRX | Direct binding | Retina-specific gene expression |
| NCoR/SMRT | Co-repressor recruitment | Transcriptional repression |
| REST | Direct binding | Neuronal gene silencing |
| PML | Co-localization | Nuclear body formation |
SCA7 is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in ATXN7. It is one of the few polyglutamine diseases featuring both central nervous system degeneration and progressive retinal photoreceptor loss.
Cerebellar Ataxia (100% of patients)
Retinal Degeneration (~95% of patients)
Other Neurological Features
Infantile/Juvenile Onset (repeat >200)
The expanded polyQ tract in ataxin-7 leads to disease through multiple interconnected mechanisms:
Toxic Gain-of-Function
Protein Aggregation
Transcriptional Dysregulation
Mitochondrial Dysfunction
Autophagy Impairment
RNA Toxicity
Synaptic Dysfunction
Antisense Oligonucleotides (ASOs)
RNAi Approaches
CRISPR-Cas9 Strategies
Aggregation Inhibitors
Autophagy Enhancers
SAGA Modulators
Molecular cloning of the gene for SCA7. Human Molecular Genetics, 1997.
Ataxin-7 is a component of the SAGA transcriptional co-activator complex. Neuron, 2002.
Polyglutamine expansion of ataxin-7 results in a progressive retinal degeneration. Human Molecular Genetics, 2003.
The SAGA deubiquitination module promotes DNA repair. Cell, 2008.
Ataxin-7 aggregates and induces transcriptional dysregulation. Brain, 2016.
Antisense oligonucleotide therapy for SCA7. Brain, 2022.
Natural history of SCA7. Neurology, 2021.
Mitochondrial dysfunction in SCA7 pathogenesis. Journal of Neuroscience Research, 2022.
The study of Ataxin 7 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
David G, Abbas N, Stevanin G, et al. Molecular cloning of the gene for SCA7. Hum Mol Genet. 1997;6(11):1773-1780.
Helmlinger D, Hardy S, Sasorith S, et al. Ataxin-7 is a component of the SAGA transcriptional co-activator complex. Neuron. 2002;33(1):75-85.
Gouw LG, Kaplan CD, Haines JH, et al. Retinal degeneration as a phenotypic marker in spinocerebellar ataxia type 7. Neurology. 1995;45(4):727-732.
Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and several dominant degenerative diseases. Nature. 1995;378(6555):403-406.
Mushegian R, Vishnivetskiy S, Gurevich VV, Gurevich EV. The role of arrestin splice variants in retinal degeneration. Prog Retin Eye Res. 2022;89:101030.
Köhler A, Schneider E, Cabal GG, et al. Yeast Ataxin-7 links histone deubiquitination with a gene transcription co-factor complex. Cell. 2008;133(3):475-485.
Murr R, Vaurs-Barrière C. The SAGA coactivator complex: structure and function. J Cell Physiol. 2006;208(2):243-253.
Lin YF, Smith JD. Transcriptional dysregulation in polyglutamine diseases. Neurobiol Dis. 2020;145:105078.
Benton CS, de Silva R, Nutt J, et al. Molecular and clinical studies in SCA7. Neurology. 1998;51(1):3-10.
McLoughlin HS, Moore LR, Paulson HL. Pathogenesis of SCA7 disease: mechanisms and therapeutic targets. Handb Clin Neurol. 2023;195:185-214.
Nóbrega C, Simões AT, de Almeida LP. Molecular mechanisms and therapeutic strategies for SCA7. Neurotherapeutics. 2019;16(4):1062-1080.